MacroGenics
MGNXMacroGenics is a clinical-stage biopharmaceutical company that utilizes proprietary antibody technology platforms to develop innovative therapeutics for cancer treatment.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
MacroGenics is a clinical-stage biopharmaceutical company that utilizes proprietary antibody technology platforms to develop innovative therapeutics for cancer treatment. The company leverages its expertise in antibody engineering to create multi-specific antibodies and antibody-drug conjugates (ADCs) designed to improve upon standard treatments through enhanced immune system engagement and targeted cell killing. Beyond its internal pipeline, the company operates a commercial-scale manufacturing facility and generates revenue through strategic collaborations and contract manufacturing services.
A clinical-stage innovator in multi-specific antibody engineering with three FDA-approved products originated from its platform and a robust network of global biopharmaceutical collaborations.
Questions, answered.
- What is MacroGenics's market cap?
- MacroGenics (MGNX) has a market capitalization of $290.5M and trades on NASDAQ.
- Who are MacroGenics's competitors?
- MacroGenics's key competitors include AstraZeneca plc, Amgen Inc., Pfizer Inc., and others. These companies compete in similar markets and product categories.
- Who does MacroGenics partner with?
- MacroGenics's notable partners include Gilead Sciences, Inc., Incyte Corporation, Sanofi S.A., and others.
- Where is MacroGenics headquartered?
- MacroGenics is headquartered in United States of America and employs approximately 339 people. It has been publicly traded since 2013.